C
Cardioxyl Pharmaceuticals
Develops and commercializes therapies for the treatment of cardiovascular disease
About Cardioxyl Pharmaceuticals
Cardioxyl Pharmaceuticals is a biotechnology company dedicated to developing innovative therapies for cardiovascular diseases, particularly heart failure and arrhythmias. The company operates in the biopharmaceutical market, targeting healthcare providers and patients who suffer from severe cardiovascular conditions. Cardioxyl's business model revolves around research and development (R&D) of novel drug candidates, which are then brought to market through clinical trials and regulatory approvals. Revenue is generated through the commercialization of these therapies, either directly or through partnerships with larger pharmaceutical companies. The company leverages its expertise in cardiovascular biology and medicinal chemistry to create treatments that address unmet medical needs, aiming to improve patient outcomes and quality of life.
Source: Dealroom company dataAt a glance
- Founded
- 2005
- Headquarters
- Chapel Hill, United States
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tier
Knowledge graph
More headlines
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Patents
16 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cardioxyl Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cardioxyl Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.